"One year after the FDA rejected Ampligen (poly I:poly C12U), manufacturer Hemispherx Biopharma Inc. has asked for up to another year to resubmit data on its New Drug Application (NDA)."
Read more: Another Delay: Ampligen for Chronic Fatigue Syndrome:
No comments:
Post a Comment